Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that it has completed ... News-Medical.Net, 3 days ago
Acucela Completes Enrollment in the Emixustat Hydrochloride Phase 2b/3 Clinical Trial - 4 Traders, 3 days ago
Acucela Inc. Completes Enrollment In The Emixustat Hydrochloride Phase 2b/3 Clinical Trial - BioSpace, 2 days ago
2 images for "Emixustat Hydrochloride"
Acucela, a US-based clinical-stage biotechnology firm, has completed the patient enrollment in its ongoing Phase IIb/III clinical trial evaluating emixustat in subjects with geographic atrophy (GA) associated with dry age-related macular ...Pharmaceutical Business Review, 3 days ago
: This year is forecast to be a record year for initial public offerings (IPOs). Over the January to March period, some 250 to 300 new issues will launch, according to professional services firm EY - a number not seen since the start of the 2008 ...Money Morning, 4 weeks ago
on your WebpageAdd Widget >Get your members hooked!